ART3 (ADP-ribosyltransferase 3) is a member of the ART family of enzymes that catalyze the transfer of ADP-ribose groups to target proteins, influencing their function. Unlike ART1 and ART2. which are well-characterized NAD⁺-dependent ecto-enzymes, ART3 is a glycosylphosphatidylinositol (GPI)-anchored protein predominantly expressed in testis, brain, and certain cancers. Its physiological role remains less understood, though studies suggest involvement in cell signaling, DNA repair, and immune regulation. ART3 antibodies are critical tools for detecting ART3 expression in tissues or cells, enabling research into its localization, expression patterns, and potential pathological roles. For example, upregulated ART3 has been observed in prostate cancer, glioblastoma, and other malignancies, where it may promote tumor survival or invasiveness. Commercially available antibodies (polyclonal or monoclonal) are typically validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. However, challenges persist in specificity due to homology with other ART family members. Recent studies also explore ART3’s interaction with extracellular NAD⁺ and its role in modulating purinergic signaling. Further research using ART3 antibodies could clarify its mechanistic contributions to disease and its potential as a therapeutic target.